203Pb-VMT-α-NET Scintigraphy of a Patient with Neuroendocrine Tumor

Dirk Müller, Hendrik Herrmann, Michael K. Schultz, Christoph Solbach, Thomas Ettrich, Vikas Prasad

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations


In an end-stage midgut neuroendocrine tumor patient with carcinoid heart disease, right ventricular dysfunction, mildly reduced renal function, and refractory to 6 cycles of 177Lu-HA-DOTATATE therapy, planar, and 22 hours SPECT/CT images were acquired after injection of 224 MBq of 203Pb-VMT-α-NET to assess the feasibility of performing 212Pb-VMT-α-NET therapy. A comparison of the 1.5 and 22 hours SPECT/CT images with 68Ga-HA-DOTATATE PET/CT showed high uptake of 203Pb-VMT-α-NET in liver metastases matching with the results of the PET/CT investigation.

Original languageEnglish
Pages (from-to)54-55
Number of pages2
JournalClinical nuclear medicine
Issue number1
StatePublished - Jan 1 2023


  • Pb
  • Pb
  • Tyr3-octreotide
  • VMT-α-NET


Dive into the research topics of '203Pb-VMT-α-NET Scintigraphy of a Patient with Neuroendocrine Tumor'. Together they form a unique fingerprint.

Cite this